9-120952759-T-C
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BP4_Strong
The NM_001735.3(C5):āc.5011A>Gā(p.Ile1671Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000279 in 1,613,580 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Consequence
NM_001735.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
C5 | NM_001735.3 | c.5011A>G | p.Ile1671Val | missense_variant | 41/41 | ENST00000223642.3 | NP_001726.2 | |
C5 | NM_001317163.2 | c.5029A>G | p.Ile1677Val | missense_variant | 41/41 | NP_001304092.1 | ||
C5-OT1 | NR_148450.1 | n.73A>G | non_coding_transcript_exon_variant | 1/2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
C5 | ENST00000223642.3 | c.5011A>G | p.Ile1671Val | missense_variant | 41/41 | 1 | NM_001735.3 | ENSP00000223642.1 |
Frequencies
GnomAD3 genomes AF: 0.0000985 AC: 15AN: 152238Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251386Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135872
GnomAD4 exome AF: 0.0000205 AC: 30AN: 1461224Hom.: 0 Cov.: 31 AF XY: 0.0000206 AC XY: 15AN XY: 726942
GnomAD4 genome AF: 0.0000985 AC: 15AN: 152356Hom.: 0 Cov.: 32 AF XY: 0.000161 AC XY: 12AN XY: 74510
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 16, 2021 | The c.5011A>G (p.I1671V) alteration is located in exon 41 (coding exon 41) of the C5 gene. This alteration results from a A to G substitution at nucleotide position 5011, causing the isoleucine (I) at amino acid position 1671 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Complement component 5 deficiency;C3810402:Eculizumab, poor response to Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Dec 30, 2021 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 30, 2023 | This variant is present in population databases (rs374914766, gnomAD 0.008%). This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 1671 of the C5 protein (p.Ile1671Val). This variant has not been reported in the literature in individuals affected with C5-related conditions. ClinVar contains an entry for this variant (Variation ID: 1444040). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on C5 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at